ClinicalTrials.gg
Not yet recruitingNCT07012512Updated Jun 10, 2025

Adjusted Study Protocol: Within-Subject Paired-Eye Design Comparing Pilocarpine 0.1%, Phentolamine 0.75%, and Combination Therapy for Cyclopentolate Reversal in Children

An interventional study of Use of phentolamine eye drops to reverse cycloplegia and Pilocarpine 0.1% in Pupillary Constriction and Accomodation, sponsored by Mansoura University. Not yet recruiting. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Mansoura University · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
5 Years to 12 Years
Sex
All
01

Study summary

The study aims at reversing pupillary dilatation. and cycloplegia in children undergoing cycloplegic refraction for eyeglasses prescription and ocular examination. This will be achieved using pilocarpine , phentolamine or a combination. This may help decrease the glare and improve near vision early to decrease unwanted effects of cycloplegic drops.

Read the detailed description

To compare the efficacy of pilocarpine 0.1%, phentolamine 0.75%, and combined therapy in reversing cyclopentolate-induced cycloplegia/mydriasis in pediatric patients using a within-subject paired-eye design (treated vs. untreated eye).

Interventions

Cycloplegia Induction:

Both eyes receive cyclopentolate 1% (2 drops, 5 minutes apart). Then cycloplegic effect confirmed at 30 minutes (accommodation ≤2 D, pupil ≥6 mm).

Reversal Agents (administered at 30 minutes post-cyclopentolate):

Pilocarpine group: Pilocarpine 0.1% (1 drop) in the study eye; placebo in the control eye.

Phentolamine group: Phentolamine 0.75% (1 drop) in the study eye; placebo in the control eye.

Combination: Pilocarpine 0.1% + phentolamine 0.75% (1 drop each) in the study eye; placebo in the control eye.

02

Conditions studied

  • Pupillary Constriction
  • Accomodation
03

In context

Lead sponsor

Mansoura University is the lead sponsor of 1,120 studies on the registry; 183 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children between 5 and 12 years undergoing cycloplegia

Exclusion criteria

Exclusion Criteria:

  • Patient refusal
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Pilocarpine group

    Children will receive pilocarpine drops in one eye and placebo in the other

    Drug: Pilocarpine 0.1%

  • Active comparator
    Phentolamine group

    Children will receive phentolamine eye drop in one eye and placebo in the other

    Drug: Use of phentolamine eye drops to reverse cycloplegia

  • Experimental
    Combined

    Children will receive a combination of pilocarpine and placebo in one eye and placebo in the other

    Drug: Combination of pilocarpine 0.1% and phentolamine 0.75%

Interventions

  • DrugUse of phentolamine eye drops to reverse cycloplegia

    Use of phentolamine 0.75% eye drops to reverse cycloplegia

  • Use of pilocarpine 0.1% to reverse cycloplegia

  • DrugCombination of pilocarpine 0.1% and phentolamine 0.75%

    Drug pages: Pilocarpine · Phentolamine

    Combination of pilocarpine 0.1% and phentolamine 0.75%

06

What researchers measure

Primary outcomes

  1. Reversal of pupillary dilatation

    Time frame: Hourly for four hours after administration of the drug

Secondary outcomes

  1. Recovery of accommodation after instillation of the drop

    Time frame: Hourly for four hours after administration of the drug

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Dec 2025, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 10, 2025
StartEst.
Jun 1, 2025
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 30, 2025
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07012512
Responsible party
Sponsor
First posted
Jun 10, 2025
Start date
Jun 1, 2025 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Jun 10, 2025

Study contacts

Ahmed AlNagdy
Contact
imanatta@mans.edu.eg
+201096710982

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pilocarpine · Phentolamine

Start the discussion